| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/30/2013 | US8497355 Anti-glypican-3 antibody having improved kinetics in plasma |
| 07/30/2013 | US8497354 Antibodies to endoplasmin and their use |
| 07/30/2013 | US8497351 Nucleic acid and corresponding protein entitled 162P1E6 useful in treatment and detection of cancer |
| 07/30/2013 | US8497246 Using blood brain barrier receptor specific immunoglobullin as diagnostic and therapeutic for prevention, detection treatment of brain disorders |
| 07/30/2013 | US8497081 Botulinum toxin screening assays |
| 07/30/2013 | US8496942 Therapeutic peptides and uses thereof |
| 07/30/2013 | US8496941 Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same |
| 07/30/2013 | US8496940 Prevention and treatment of sub-clinical PCVD |
| 07/30/2013 | US8496939 An adjuvant is used in vaccine formulation, comprising a polymeric emulsifier Arlacel" or ATLOX"; stable, low viscosity |
| 07/30/2013 | US8496938 Anti-CD100 neutralizing neutralizing antibodies and methods of using the same |
| 07/30/2013 | US8496937 Preparation of isolated agonist anti-EDAR monoclonal antibodies |
| 07/30/2013 | US8496936 Antagonists of IL-17A, IL-17F, and IL-23P19 |
| 07/30/2013 | US8496935 Immunosuppressive polypeptides and nucleic acids |
| 07/30/2013 | US8496934 Method for treating cachexia using antagonist antibodies against GDF-8 |
| 07/30/2013 | US8496933 VHNAR anti-cytokine domains |
| 07/30/2013 | US8496932 Compounds |
| 07/30/2013 | US8496931 Monoclonal antibodies against stromal derived factor-1 (SDF-1) |
| 07/30/2013 | US8496930 Method of stabilizing antibody and stabilized solution-type antibody preparation |
| 07/30/2013 | US8496929 Generating antibodies; cardiovascular disorders |
| 07/30/2013 | CA2691091C Fusion protein, macromolecule assembled from the fusion protein, and its use in the prevention or treatment of human papillomavirus related diseases |
| 07/30/2013 | CA2678008C Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies |
| 07/30/2013 | CA2540138C Recombinant antibody against human insulin-like growth factor |
| 07/30/2013 | CA2534639C Anti-cd19 antibodies |
| 07/30/2013 | CA2526128C Severe acute respiratory syndrome dna vaccine compositions and methods of use |
| 07/30/2013 | CA2518944C Inhibitors of extracellular hsp90 |
| 07/30/2013 | CA2509241C Use of serum amyloid p (sap) and related compositions for the suppression of fibrosis-related diseases |
| 07/30/2013 | CA2502668C Fully human antibody fab fragments with human interferon-gamma neutralizing activity |
| 07/30/2013 | CA2499816C Optimized fc variants and methods for their generation |
| 07/30/2013 | CA2480079C Antiangiogenic active immunotherapy |
| 07/25/2013 | WO2013110064A1 Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen |
| 07/25/2013 | WO2013110050A1 Inulin and inulin acetate formulations |
| 07/25/2013 | WO2013110030A2 Vaccines against antigens involved in therapy resistance and methods of using same |
| 07/25/2013 | WO2013109995A2 Fused antigen vaccines and compositions against streptococcus pneumoniae |
| 07/25/2013 | WO2013109904A1 Compositions, methods and kits for treatment of cancer and autoimmune diseases |
| 07/25/2013 | WO2013109856A2 Methods of using fgf19 modulators |
| 07/25/2013 | WO2013109829A1 Anti-adamts4 antibodies and methods of treatment |
| 07/25/2013 | WO2013109825A1 Chromatographic media for storage and delivery of therapeutic biologics and small molecules |
| 07/25/2013 | WO2013109819A1 Anti-lrp5 antibodies and methods of use |
| 07/25/2013 | WO2013109759A1 Methods and compositions for expanding immunosuppressive t regulatory cells in vitro and uses thereof |
| 07/25/2013 | WO2013109604A1 Viral attenuation and vaccine production |
| 07/25/2013 | WO2013109279A2 Stabilization of the anti-cd20 antibody rituximab |
| 07/25/2013 | WO2013109185A1 Novel antibodies |
| 07/25/2013 | WO2013108869A1 Therapeutic or prophylactic agent for cancer |
| 07/25/2013 | WO2013108272A2 Blood stage malaria vaccine |
| 07/25/2013 | WO2013107988A1 Method for formulating a vaccine containing at least two antigens capable of adsorbing onto aluminium oxyhydroxide |
| 07/25/2013 | WO2013107883A1 Tetrahydrofolates in combination with egfr-inhibitors |
| 07/25/2013 | WO2013107854A1 Hiv-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens |
| 07/25/2013 | WO2013107436A1 Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens |
| 07/25/2013 | WO2013107413A1 Use of phosphorylation pathway-related factor in regulating function of regulatory t cell |
| 07/25/2013 | WO2013107355A1 Anti-hbc quantitative detection method and uses thereof in monitoring and controlling disease progression of chronic hepatitis b patient and in predicting therapeutic effect |
| 07/25/2013 | WO2013107290A1 A novel paramyxovirus and uses thereof |
| 07/25/2013 | WO2013106934A1 Novel regulators of innate immunity and uses thereof |
| 07/25/2013 | WO2013106895A1 Autologous cancer cell vaccine |
| 07/25/2013 | WO2013076702A3 Monoclonal antibodies specific for the m2-1 antigen of respiratory syncytial virus (rsv) |
| 07/25/2013 | WO2013071016A3 Methods of inhibiting tumor growth by antagonizing il-6 receptor |
| 07/25/2013 | WO2013043070A3 Anti-tumor necrosis factor-alpha agents and uses thereof |
| 07/25/2013 | WO2012156219A9 Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
| 07/25/2013 | WO2012022677A3 Combination therapy for the treatment of cancer |
| 07/25/2013 | US20130190839 Drug delivery using a sacrificial host |
| 07/25/2013 | US20130190250 Polynucleotides Encoding Human Signal Peptide-Containing Proteins |
| 07/25/2013 | US20130190247 Peptide antagonists of zonulin and methods for use of the same |
| 07/25/2013 | US20130190221 Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t-cells |
| 07/25/2013 | US20130189762 Multi plasmid system for the production of influenza virus |
| 07/25/2013 | US20130189758 Recombinant reverse transcriptases |
| 07/25/2013 | US20130189678 Macrophage migration inhibitory factor (mif) promoter polymorphism in inflammatory disease |
| 07/25/2013 | US20130189351 Lipids suitable for liposomal delivery of protein coding rna |
| 07/25/2013 | US20130189338 Bone fibers having extended length |
| 07/25/2013 | US20130189310 Autologous cancer cell vaccine |
| 07/25/2013 | US20130189308 Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines |
| 07/25/2013 | US20130189307 Method of treating depression |
| 07/25/2013 | US20130189306 Flavivirus Vaccines |
| 07/25/2013 | US20130189305 Methods of producing inflenza vaccine compositions |
| 07/25/2013 | US20130189304 Preservation of bioactive materials by freeze dried foam |
| 07/25/2013 | US20130189303 Recombinant swine influenza virus and uses thereof |
| 07/25/2013 | US20130189302 Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen |
| 07/25/2013 | US20130189295 Combinations of meningococcal factor h binding proteins |
| 07/25/2013 | US20130189294 Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 07/25/2013 | US20130189293 Influenza hemagglutinin and neuraminidase variants |
| 07/25/2013 | US20130189292 Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions |
| 07/25/2013 | US20130189290 Vaccine for the prevention of breast cancer relapse |
| 07/25/2013 | US20130189288 Adjuvant compositions and methods of use |
| 07/25/2013 | US20130189285 Antibodies against ramp3 |
| 07/25/2013 | US20130189277 Stabilized Formulations Containing Anti-PCSK9 Antibodies |
| 07/25/2013 | US20130189276 Method inhibiting cell proliferation induced by alternatively spliced tissue factor |
| 07/25/2013 | US20130189275 Compositions and methods for inhibition of or treatment of dengue virus infection |
| 07/25/2013 | US20130189274 Phosphatidylinositol-3-kinase pathway biomarkers |
| 07/25/2013 | US20130189273 Eg-vegf nucleic acids and polypeptides and methods of use |
| 07/25/2013 | US20130189272 Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen |
| 07/25/2013 | US20130189262 IL-27 Antagonists for Treating Inflammatory Diseases |
| 07/25/2013 | US20130189261 TCR Complex Immunotherapeutics |
| 07/25/2013 | US20130189257 Use of pkc-iota inhibitors for the treatment of breast cancer |
| 07/25/2013 | US20130189255 Fusions and conjugates of insulinotropic agents |
| 07/25/2013 | US20130189253 Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| 07/25/2013 | US20130189251 Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |
| 07/25/2013 | US20130189249 Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| 07/25/2013 | US20130189248 Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer |
| 07/25/2013 | US20130189224 Compositions, methods, and kits for eliciting an immune response |
| 07/25/2013 | US20130186797 Stabilized Formulations Containing Anti-Ang2 Antibodies |
| 07/25/2013 | DE112011102638T5 Pharmazeutische Zusammensetzung und Verfahren zur Behandlung und Prävention der Krankheiten, die durch HIV verursacht werden oder mit HIV zusammenhängen Related pharmaceutical composition and method for the treatment and prevention of diseases caused by HIV or HIV |
| 07/25/2013 | CA2862424A1 Methods of using fgf19 modulators |